Comparative Pharmacology
Head-to-head clinical analysis: BUMETANIDE versus LASIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUMETANIDE versus LASIX.
BUMETANIDE vs LASIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption and increasing urinary output.
0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.
20-80 mg IV or PO once or twice daily; maximum 600 mg/day IV or PO.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults; prolonged to 1.5-3 hours in renal impairment.
Clinical Note
moderateBumetanide + Digoxin
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin."
Clinical Note
moderateBumetanide + Digitoxin
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin."
Clinical Note
moderateBumetanide + Deslanoside
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Deslanoside."
Clinical Note
moderateBumetanide + Acetyldigitoxin
Terminal elimination half-life is approximately 1.5-2 hours. In renal impairment (CrCl <20 mL/min), half-life may prolong to up to 2-4 hours; in end-stage renal disease or heart failure, may exceed 4 hours.
Primarily renal (approximately 80% as unchanged drug), with minimal biliary/fecal excretion (about 10-20%).
Primarily renal excretion (50-80% as unchanged drug) via glomerular filtration and proximal tubular secretion; minor fecal elimination (<5%).
Category A/B
Category C
Loop Diuretic
Loop Diuretic
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Acetyldigitoxin."